Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
The facility is expected to become operational by FY2028-29
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
If approved, DTX401 would be the first treatment to address the disease at its root cause
Subscribe To Our Newsletter & Stay Updated
